Abstract Details

Title Disease characteristics of seropositive neuromyelitis optica spectrum disorder in a Turkish cohort

Topic Autoimmune Neurology

Presentation(s) P1 - Poster Session 1 (9:00 AM-5:00 PM)

Poster/Presentation
Number 008

Objective To determine the clinical, demographic and imaging characteristics of a Turkish cohort with aquaporin-4-antibody positive (AQP4-IgG+) neuromyelitis optica spectrum disorder (NMOSD) from a single center.

Background -

Design/Methods

35 patients seen between January-2008 and December-2020 with a diagnosis of AQP4-IgG+NMOSD who could be studied in detail were included in the study. Inclusion criteria for patients with NMOSD diagnosis was defined according to International Consensus Diagnostic Criteria (Wingerchuk et al.2015) and all patients were confirmed for AQP4-IgG positive serology at least once by Euroimmune transfected cells assay (EU90). Demographic, clinical and MRI datawere obtained retrospectively.

Results The female-to-male ratio was 16.5: 1. The mean age of disease onset was 26,16±10,96 years for patients with optic neuritis onset (n:12), and 43.17±11,95 for the subgroup that started with transverse myelitis (TM) (n:16), confirming a significant difference of age at onset according to the first attack type (p <0.001). The mean age at onset in 5 patients with area postrema syndrome was 35,74±16,83. Half of the total attacks occurred within the first year of disease onset (98/196). The mean time to diagnosis was 2,98±5,78 years after the initial attack. Disease duration was 10,06±9,76 years. Cerebrospinal fluid oligoclonal bands were studied in 24 and were positive in 25%. An autoimmune rheumatologic disease comorbidity was present in 34.5% of the patients. In patients with MRI disclosing ≥2 McDonald dissemination in space criteria (spinal included) was more common in TM group and correlated with a higher disability (EDSS) score.

Conclusions

Turkish AQP4-IgG+NMOSD patients whose disease start with optic neuritis have an earlier age of onset compared to the ones with TM onset. Half of the total attacks occur within the first year of disease onset. Patients with ≥2 McDonald MRI dissemination in space criteria were more common in the TM group and had a higher disability (EDSS) score.

Authors/Disclosures
Aksel Siva, MD (Istanbul University Cerrahpasa School of Medicine) PRESENTER	Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen - TR. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ali Raif Pharmaceuticals, Turkiye. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanovel Pharmaceuticals, Turkiye. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abdi Ibrahim Ilac - TR. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck Serono . The institution of Dr. Siva has received research support from Turkish MS Society. The institution of Dr. Siva has received research support from The Scientific and Technological Research Council Of Turkey - Health Sciences Research Grants.
Samet Cam	No disclosure on file
Bade Gulec	Bade Gulec has nothing to disclose.
Melih Tutuncu, MD	No disclosure on file
Sabahattin Saip	Sabahattin Saip has nothing to disclose.
Ugur Uygunoglu (Cerrahpasa)	Ugur Uygunoglu has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Turkey . The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen Idec/Gen Pharma of Turkey. The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck-Serono of Turkey. The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanovel of Turkey. The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Genveon of Turkey.

��ɫ��

��ɫ��